Imatinib
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Chronic Myelogenous Leukemia in Chronic Phase
Conditions
Chronic Myelogenous Leukemia in Chronic Phase
Trial Timeline
Nov 1, 2002 → Jun 1, 2007
NCT ID
NCT00237120About Imatinib
Imatinib is a phase 3 stage product being developed by Novartis for Chronic Myelogenous Leukemia in Chronic Phase. The current trial status is completed. This product is registered under clinical trial identifier NCT00237120. Target conditions include Chronic Myelogenous Leukemia in Chronic Phase.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (12)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01392495 | Phase 3 | Terminated |
| NCT01137916 | Phase 2 | Completed |
| NCT00760981 | Phase 1 | Completed |
| NCT00632255 | Pre-clinical | Completed |
| NCT00426179 | Phase 1/2 | Completed |
| NCT00420043 | Phase 1 | Completed |
| NCT00424515 | Phase 2 | Completed |
| NCT00422825 | Phase 1 | Completed |
| NCT00421317 | Phase 2 | Terminated |
| NCT00150072 | Phase 2 | Completed |
| NCT00237120 | Phase 3 | Completed |
| NCT00940563 | Phase 2 | Completed |
Competing Products
20 competing products in Chronic Myelogenous Leukemia in Chronic Phase
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| macitentan 10 mg | BML, Inc. | Phase 3 | 76 |
| KPL-716 + Placebo | Kiniksa Pharmaceuticals | Phase 2 | 47 |
| TERN-701 | Terns Pharmaceuticals | Phase 1/2 | 38 |
| Fludarabine + Cyclophosphamide + PRGN-3007 | Precigen | Phase 1 | 28 |
| LY3556050 + Placebo | Eli Lilly | Phase 2 | 52 |
| THB001 | Third Harmonic Bio | Phase 1 | 25 |
| Briquilimab | Jasper Therapeutics | Phase 1/2 | 33 |
| Briquilimab | Jasper Therapeutics | Phase 1/2 | 33 |
| Briquilimab | Jasper Therapeutics | Phase 2 | 44 |
| Empagliflozin + Matching placebo | Eli Lilly | Phase 3 | 77 |
| LY3461767 + Placebo | Eli Lilly | Phase 1 | 33 |
| Pirtobrutinib + Venetoclax + Rituximab | Eli Lilly | Phase 3 | 77 |
| LY3526318 + Placebo | Eli Lilly | Phase 2 | 52 |
| Pirtobrutinib | Eli Lilly | Phase 2 | 52 |
| Ibrutinib + LY3214996 | Eli Lilly | Phase 1 | 33 |
| Pirtobrutinib + Acalabrutinib | Eli Lilly | Phase 2 | 52 |
| LYR-210 | Lyra Therapeutics | Phase 2 | 44 |
| LYR-220 Design 1 (Part 1 only) + LYR-220 Design 2 (Part 1 and Part 2) + Bilateral sham procedure control (Part 2) | Lyra Therapeutics | Phase 2 | 44 |
| 480 Mometasone Furoate Sinus Drug Depot | Lyra Therapeutics | Phase 1 | 25 |
| LYR-210 + Sham procedure control | Lyra Therapeutics | Phase 3 | 69 |